Innovación en salud en México: retos importantes y un largo camino que recorrer / Health innovation in Mexico: important challenges and a long road to walk

Resumen: La transferencia de tecnología de instituciones de investigación en salud a empresas que generen nuevos tratamientos médicos ha generado grandes beneficios para la salud pública a nivel mundial. Sin embargo, en México existen importantes rezagos en los indicadores de innovación. Hay barreras culturales, regulatorias y financieras que obstaculizan la innovación en México. Al mismo tiempo, los últimos años han visto la aparición de varias iniciativas útiles que avanzan en la dirección correcta. El presente trabajo describe la situación actual y las principales barreras y oportunidades para promover la innovación en salud y la contribución de ésta a mejoras en salud pública.

Abstract: The transfer of technology from health research institutions to businesses that develop new medical treatments has generated great benefits for public health at a global level. Mexico however, is lagging in innovation indicators. There are important cultural, regulatory, and financial barriers that limit innovation in Mexico. However recent years have seen the appearance of several useful initiatives that constitute progress in the right direction. This work provides a brief overview of the current situation of innovation in Mexico, describes the main barriers and gives recommendations that can promote health innovation in Mexico, which can contribute to improvements in public health.

[Health innovation in Mexico: important challenges and a long road to walk]. / Innovación en salud en México: retos importantes y un largo camino que recorrer.

The transfer of technology from health research institutions to businesses that develop new medical treatments has generated great benefits for public health at a global level. Mexico however, is lagging in innovation indicators. There are important cultural, regulatory, and financial barriers that limit innovation in Mexico. However recent years have seen the appearance of several useful initiatives that constitute progress in the right direction. This work provides a brief overview of the current situation of innovation in Mexico, describes the main barriers and gives recommendations that can promote health innovation in Mexico, which can contribute to improvements in public health.

La transferencia de tecnología de instituciones de investigación en salud a empresas que generen nuevos tratamientos médicos ha generado grandes beneficios para la salud pública a nivel mundial. Sin embargo, en México existen importantes rezagos en los indicadores de innovación. Hay barreras culturales, regulatorias y financieras que obstaculizan la innovación en México. Al mismo tiempo, los últimos años han visto la aparición de varias iniciativas útiles que avanzan en la dirección correcta. El presente trabajo describe la situación actual y las principales barreras y oportunidades para promover la innovación en salud y la contribución de ésta a mejoras en salud pública.

Uso y aplicación de la tecnología de impresión y bioimpresión 3D en medicina / Use and application of 3D printing and bioimpression technology in medicine

RESUMEN En el mundo actual, las llamadas "tecnologías de fabricación por adición" o impresión 3D también llamado prototipado rápido, han trascendido las fronteras de casi todos los campos de la ciencia, y su incursión en la medicina es cada vez mayor. Es justamente en el campo médico que esta tecnología de impresión por adición ha evolucionado a la bioimpresión, que incluye un proceso de cultivo celular en laboratorio haciendo posible la formación de órganos y/o tejidos personalizados. Para la impresión tridimensional de órganos en humanos se toman muestras de un tejido o células madre del paciente, para ser cultivadas y expandidas en laboratorio para su posterior diferenciación a una línea celular específica. Para este proceso se utiliza un material sólido como andamio a temperatura ambiente con un punto de fusión conocido. En la creación de un modelo para la fabricación de un órgano o tejido en impresión 3D, se utilizan los estudios de imágenes médicas de los pacientes intentando preservar al máximo la anatomía de las estructuras que se desean reproducir. En este artículo se abordan las bases y el potencial uso de esta tecnología en el área médica.

ABSTRACT In today's world, so-called "addition manufacturing technologies" or 3D printing also called rapid prototyping have transcended the borders of almost every field of science and medicine is no exception. It is not surprising that its exploration for practical uses is increasing. In medicine, this technology of printing by addition has evolved to bioprinting, which occurs by a special process, from cells grown in a laboratory, which makes possible its transformation into a type of organs tailored to the patient. The three-dimensional impression of human organs requires take samples of tissues or stem cells from the patient, which are grown in the laboratory waiting to multiply or differentiate to other cell lines; then, to create said object, a solid material at room temperature and with a known melting point is applied layer by layer. Currently the use of this technology uses the medical images of patients trying to preserve the anatomy of the structures that they want to reproduce. In this article the bases and the potential use of this technology in the medical area will be addressed.

Behavior of multipotent stem cells isolated in mobilized peripheral blood from sheep after culture with human chondrogenic medium.

Today, regenerative medicine requires new sources of multipotent stem cells for their differentiation to chondrocytes using the mediums of differentiation available in the market. This study aimed to determine whether the Mesenchymal Stem Cells (MSCs) isolated from Mobilized Peripheral Blood (MPB) in sheep using the Granulocyte Colony-Stimulating Factor (G-CSF), have the ability of first acquire a fibroblast-like morphology after being forced out of the bone marrow niche by G-CSF and second, if the cells have the capacity to express collagen type-II α I in primary culture using a human commercial media of differentiation. Six Suffolk male sheep with age of 2 years were mobilized using G-CSF. One subcutaneous injection of 10 mcg per kilogram of bodyweight were administered every 24 h during three consecutive days. At day four, a sample of 20 mL of peripheral blood was harvested, afterwards, monocytes cells were separated by ficoll gradient. The mobilized MSCs were expanded in primary culture in DMEM medium supplemented with 10% adult sheep serum for three weeks and characterized by an antibody panel for surface markers: CD105, CD90, CD73, CD34, and CD45, before and after primary culture. Subsequently, an aliquot of cells in the first pass were cultured in a commercial human chondrogenic medium for three weeks. As a result, the percentage of surface markers for MSCs (CD105, CD90, CD73) in expanded cells in primary culture significantly increased, at the same time a decrease in the markers for hematopoietic cells (CD34 and CD45) was observed and the cells morphology was fibroblast-like. After three weeks of differentiation culture, the immunofluorescence analysis evidenced the expression of collagen-type-II. It was concluded that Mesenchymal Stem Cells isolated from mobilized peripheral blood in sheep have the ability to pre-differentiate into chondral like cells and express collagen type-II when are stimulated with a human commercial chondrogenic medium in monolayer culture.

Co-culture of dedifferentiated and primary human chondrocytes obtained from cadaveric donor enhance the histological quality of repair tissue: an in-vivo animal study.

To compare the quality of the repair tissue in three-dimensional co-culture of human chondrocytes implanted in an in vivo model. Six cadaveric and five live human donors were included. Osteochondral biopsies from the donor knees were harvested for chondrocyte isolation. Fifty percent of cadaveric chondrocytes were expanded until passage-2 (P2) while the remaining cells were cryopreserved in passage-0 (P0). Fresh primary chondrocytes (P0f) obtained from live human donors were co-cultured. Three-dimensional constructs were prepared with a monolayer of passage-2 chondrocytes, collagen membrane (Geistlich Bio-Gide®), and pellet of non-co-cultured (P2) or co-cultured chondrocytes (P2 + P0c, P2 + P0f). Constructs were implanted in the subcutaneous tissue of athymic mice and left for 3 months growth. Safranin-O and Alcian blue staining were used to glycosaminoglycan content assessment. Aggrecan and type-II collagen were evaluated by immunohistochemistry. New-formed tissue quality was evaluated with an adaptation of the modified O'Driscoll score. Histological quality of non-co-cultured group was 4.37 (SD ±4.71), while co-cultured groups had a mean score of 8.71 (SD ±3.98) for the fresh primary chondrocytes and 9.57 (SD ±1.27) in the cryopreserved chondrocytes. In immunohistochemistry, Co-culture groups were strongly stained for type-II and aggrecan not seen in the non-co-cultured group. It is possible to isolate viable chondrocytes from cadaveric human donors in samples processed in the first 48-h of dead. There is non-significant difference between the numbers of chondrocytes isolated from live or cadaveric donors. Cryopreservation of cadaveric primary chondrocytes does not alter the capability to form cartilage like tissue. Co-culture of primary and passaged chondrocytes enhances the histological quality of new-formed tissue compared to non-co-cultured cells.

Serum tumor markers in pediatric osteosarcoma: a summary review.

Osteosarcoma is the most common primary high-grade bone tumor in both adolescents and children. Early tumor detection is key to ensuring effective treatment. Serum marker discovery and validation for pediatric osteosarcoma has accelerated in recent years, coincident with an evolving understanding of molecules and their complex interactions, and the compelling need for improved pediatric osteosarcoma outcome measures in clinical trials. This review gives a short overview of serological markers for pediatric osteosarcoma, and highlights advances in pediatric osteosarcoma-related marker research within the past year. Studies in the past year involving serum markers in patients with pediatric osteosarcoma can be assigned to one of four categories, i.e., new approaches and new markers, exploratory studies in specialized disease subsets, large cross-sectional validation studies, and longitudinal studies, with and without an intervention.Most of the studies have examined the association of a serum marker with some aspect of the natural history of pediatric osteosarcoma. As illustrated by the many studies reviewed, several serum markers are emerging that show a credible association with disease modification. The expanding pool of informative osteosarcoma-related markers is expected to impact development of therapeutics for pediatric osteosarcoma positively and, it is hoped, ultimately clinical care. Combinations of serum markers of natural immunity, thyroid hormone homeostasis, and bone tumorigenesis may be undertaken together in patients with pediatric osteosarcoma. These serum markers in combination may do better. The potential effect of an intrinsic dynamic balance of tumor angiogenesis residing within a single hormone (tri-iodothyronine) is an attractive concept for regulation of vascularization in pediatric osteosarcoma.

Técnica para realizar el tunel femoral a través del portal anteromedial en la reconstrucción del ligamento cruzado anterior / Using the anteromedial portal for anterior cruciate ligament reconstruction

La perforación del túnel femoral a través del portal anteromedial permite la colocación anatómica del túnel femoral, es indispensable en la reconstrucción con doble banda y en la técnica todo adentro. Existen varios retos y complicaciones cuando se toma la decisión de realizar esta técnica, los cuales deben ser conocidos por el cirujano antes de llevar a cabo este procedimiento. El propósito de esta revisión es describir los pasos a seguir para los cirujanos que contemplan realizar el túnel femoral a través del portal anteromedial para la reconstrucción del ligamento cruzado anterior.

Técnica para realizar el tunel femoral a través del portal anteromedial en la reconstrucción del ligamento cruzado anterior / Using the anteromedial portal for anterior cruciate ligament reconstruction

La perforación del túnel femoral a través del portal anteromedial permite la colocación anatómica del túnel femoral, es indispensable en la reconstrucción con doble banda y en la técnica todo adentro. Existen varios retos y complicaciones cuando se toma la decisión de realizar esta técnica, los cuales deben ser conocidos por el cirujano antes de llevar a cabo este procedimiento. El propósito de esta revisión es describir los pasos a seguir para los cirujanos que contemplan realizar el túnel femoral a través del portal anteromedial para la reconstrucción del ligamento cruzado anterior (AU)

[Clinical-ultrasonographic assessment in arthroscopic rotator cuff repair after 1-year follow-up]. / Evaluación clínico-ultrasonográfica en la reparación artroscópica del mango rotador a 1 año de seguimiento postoperatorio.

INTRODUCTION: Arthroscopic repair of the rotator cuff have shown have shown encouraging clinical results. However, few authors have assessed integrity of repair with ultrasound. The presence of re-rupture by ultrasonography in a rotator cuff repair may not relate to the patient's functional status. OBJECTIVE: We used ultrasonography to assess the prevalence of re-rupture in rotator cuff repairs and its clinical relevance with minimum 1 year postoperatively. MATERIALS AND METHODS: Evidence level IV (Case series). We evaluated 27 shoulders that underwent arthroscopic rotator cuff repair. Clinical evaluation was performed using UCLA functional scale, visual analogue scale (UCLA, VAS). Post-operative ultrasound was performed at least 1 year postoperatively. Statistical analysis was done with the SPSS 11.0 software. RESULTS: We examined 27 shoulders, mean age 56.4 (41-78), mean postoperative follow-up 19.6 (12 m-88 m). Clinical assessment with UCLA functional scale results were: good-excellent (77.4%); fair (22.2%). VAS results showed that 44.4% reported VAS of 0; in the range of 1-3 VAS was 55.5% of the patients. Ultrasound evaluation showed no injury in 37%; partial lesion 51.9%, and a total lesion 11.1%. Thirty-three % of the patients with VAS of 0 showed no injury when evaluated by ultrasonography, injury by ultrasound 33.3% with VAS (1-3) 22.2%. UCLA (good-excellent) without injury by ultrasound 33.3% with a 44.4% degree of injury, UCLA (Fair) without injury 3.7%, with some degree of lesion 18.5%. Results no statistically significant difference (p > 0.05). CONCLUSIONS: In our series, we find that integrity of rotator cuff postoperative ultrasound, it has no effect on the functional status of patients with postoperative follow-up of at least 1 year, with UCLA and VAS.

Minimally invasive quadriceps tendon harvest.

Quadriceps tendon (QT) is becoming a popular graft for primary and revision ligament surgery. A subcutaneous technique for graft harvesting a QT is presented. Special closed tendon strippers were designed; these devices have 10- and 11-mm inner diameters and are stronger and sharper than regular hamstrings strippers. In the mid-line of the patellar upper pole, a 2-cm longitudinal incision is made, a 20- x 10-mm bone plug is created with an oscillating saw, and the tendon stripper is positioned and advanced into the thigh, dissecting the QT until the desired length, usually 10 cm, is obtained. The graft can be released by making a stab incision at the device's tip or by ventrally pointing and turning the tendon stripper to amputate the graft's end. The QT graft can be prepared in several fashions for 1- or 2-bundle ligament reconstructions. The technique was tested and refined in 3 cadaver specimens and has been used at our institution since 2003 in 18 primary posterior cruciate ligament reconstructions with no problems. This minimally invasive technique is safe, provides a consistently good-quality graft with excellent cosmetic results, and is simple and easily reproducible.